A randomized clinical trial of trimetazidine, a partial free fatty acid oxidation inhibitor, in patients with heart failure. - Wikidata - wikimedia - TriplyDB

A randomized clinical trial of trimetazidine, a partial free fatty acid oxidation inhibitor, in patients with heart failure.

A randomized clinical trial of trimetazidine, a partial free fatty acid oxidation inhibitor, in patients with heart failure.

http://www.wikidata.org/entity/Q34562883

about

Recent advances in the management of chronic stable angina II. Anti-ischemic therapy, options for refractory angina, risk factor reduction, and revascularization.The role of trimetazidine in cardiovascular disease: beyond an anti-anginal agent Review of novel therapeutic targets for improving heart failure treatment based on experimental and clinical studies Cardiac energy metabolic alterations in pressure overload-induced left and right heart failure (2013 Grover Conference Series)Mitochondrial fatty acid oxidation alterations in heart failure, ischaemic heart disease and diabetic cardiomyopathy Optimization of cardiac metabolism in heart failure Metabolic dysfunction in pulmonary hypertension: the expanding relevance of the Warburg effect Targeting myocardial substrate metabolism in heart failure: potential for new therapies Present and future pharmacotherapeutic agents in heart failure: an evolving paradigm Is treatment with trimetazidine beneficial in patients with chronic heart failure?Treatment with the 3-ketoacyl-CoA thiolase inhibitor trimetazidine does not exacerbate whole-body insulin resistance in obese mice.Metabolic Dysfunction in Heart Failure: Diagnostic, Prognostic, and Pathophysiologic Insights From Metabolomic Profiling.Imaging and modeling of myocardial metabolism Trimetazidine protects against smoking-induced left ventricular remodeling via attenuating oxidative stress, apoptosis, and inflammation Allopurinol acutely increases adenosine triphospate energy delivery in failing human hearts.Modulating fatty acid oxidation in heart failure.Nanoscale three-dimensional imaging of the human myocyte.Diabetic cardiac autonomic neuropathy: Do we have any treatment perspectives?Structure-activity-relationship study of N-acyl-N-phenylpiperazines as potential inhibitors of the Excitatory Amino Acid Transporters (EAATs): improving the potency of a micromolar screening Hit is not truism.Altered serum levels of IL-33 in patients with advanced systolic chronic heart failure: correlation with oxidative stress.C-Myc induced compensated cardiac hypertrophy increases free fatty acid utilization for the citric acid cycle Emerging drugs for acute and chronic heart failure: current and future developments.Advanced chronic heart failure: A position statement from the Study Group on Advanced Heart Failure of the Heart Failure Association of the European Society of Cardiology.Early administration of trimetazidine attenuates diabetic cardiomyopathy in rats by alleviating fibrosis, reducing apoptosis and enhancing autophagy Reverse changes in cardiac substrate oxidation in dogs recovering from heart failure.Free fatty acids as a cardiovascular risk factor.Metabolic remodelling of the failing heart: beneficial or detrimental?Metabolic modulation and cellular therapy of cardiac dysfunction and failure.The effects of trimetazidine on lipopolysaccharide-induced oxidative stress in mice.Potential of metabolic agents as adjunct therapies in heart failure.PPARs as therapeutic targets in cardiovascular disease.Metabolic remodelling in human heart failure.Use of inotropic agents in patients with advanced heart failure: lessons from recent trials and hopes for new agents.Evaluation of trimetazidine in angina pectoris by echocardiography and radionuclide angiography: a meta-analysis of randomized, controlled trials.Update on diastolic heart failure or heart failure with preserved ejection fraction in the older adults.Recent advances in metabolic imaging.Defining the role of trimetazidine in the treatment of cardiovascular disorders: some insights on its role in heart failure and peripheral artery disease.Pharmacological update: New drugs in cardiac practice: A critical appraisal Pharmacological Agents Targeting Myocardial Metabolism for the Management of Chronic Stable Angina : an Update.Metabolic support for the heart: complementary therapy for heart failure?

P2860

Q24605881-488E1A2D-D39B-42B4-8B86-65AFB63D913B Q26741061-412BEB1B-33DB-42DA-ACD4-3C6E15E04D93 Q26746907-5AA3881E-B21C-466D-9800-83D60BE39A0D Q26825047-EB089E9D-2DC0-4B65-BD76-582D37998FE4 Q26859582-B9CECF7A-3DED-4FCF-8ED2-58373F2B4A97 Q27023021-33903DD2-A84B-4B0C-A28F-BB4DC4DDB705 Q27024293-837C259F-6627-4C93-9259-0ED9B3AB2B7F Q27694733-5F19245A-F4DD-431D-BE49-603FD7819843 Q28077186-D2D0DF04-D038-4D30-9777-16E34782CB07 Q33567682-4A41734E-1CB6-4E27-AE29-3C5B01F951A0 Q33603593-B6F2EC39-0FAD-45A3-8386-407042B5417A Q33892283-316CADB1-90CC-42AC-8790-95F0928C924B Q33970067-650B32E7-AB44-4A1D-BCAD-8947100FD3B3 Q34336231-720AD085-EA69-4541-AAF0-68297A415BEB Q34398552-553102A3-A061-4AD8-9089-5F001DFA9B28 Q34808505-1861956D-2AC3-4595-B368-B73BDC53A48E Q34966915-B0A58A67-020E-49F6-A950-7818D5FE1C52 Q35179226-3B5D992F-5C4B-42C5-88AD-7D4C340AA578 Q35532022-B6720B8D-F167-4900-93CD-3FCE08D93940 Q36445023-6C6BC213-FA55-4BCD-9948-CC5311BF9E5B Q36472714-AE3197F9-712D-442A-B274-EB956F7A3148 Q36758585-0DDF6A6C-C374-430C-AD69-A84CB53471F5 Q36811824-8251BF99-101F-48F4-BEBC-A15364F9EF98 Q36846777-FF0F8778-D287-4E55-A0C3-4A297D5EF596 Q37038911-4339D9ED-C098-4896-B4AD-F03C2C5E0DB9 Q37208848-622D3B88-54AF-468F-8200-835EF6E2F58D Q37293624-2EBD3C5E-A8E2-4008-B4A4-F0A72A46EE2D Q37296154-6A74691D-4FCC-41BC-AB8E-A9CE060C5CED Q37413807-C4C30BAC-C968-45BC-9017-363E4D10976C Q37608595-D528B32C-952F-4D32-AB79-E5AFB1E0BDBA Q37790384-285BB6FD-7807-45FF-A371-E49A24159637 Q37849446-92DB901F-AC55-4C05-819C-D840F8CAF7F9 Q37858515-A8C71CB2-D0D4-4940-8315-37E6845E40F5 Q37871496-AA96715A-CE48-4F3F-B429-71E3A7845BE9 Q37993133-338844E2-54F8-4D8C-B914-460A2570E4BF Q38156683-8FB030DB-BA1F-4C35-B916-AADDA7CE7437 Q38217985-6C7EB197-C5DE-4AB0-9E3C-24C34C2F5629 Q38772000-67AE45B9-EBBC-477C-B864-60F0C03DE382 Q38920729-C61B4B49-58A3-44D2-B56E-CC08E11967CA Q38998576-938128F0-564B-4B82-9155-3EAAF81C77BB

P2860

A randomized clinical trial of trimetazidine, a partial free fatty acid oxidation inhibitor, in patients with heart failure.

http://www.wikidata.org/entity/Q34562883

description

2006 nî lūn-bûn

@nan

2006 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

A randomized clinical trial of ...... n patients with heart failure.

@ast

A randomized clinical trial of ...... n patients with heart failure.

@en

A randomized clinical trial of ...... n patients with heart failure.

@nl

type

label

A randomized clinical trial of ...... n patients with heart failure.

@ast

A randomized clinical trial of ...... n patients with heart failure.

@en

A randomized clinical trial of ...... n patients with heart failure.

@nl

prefLabel

A randomized clinical trial of ...... n patients with heart failure.

@ast

A randomized clinical trial of ...... n patients with heart failure.

@en

A randomized clinical trial of ...... n patients with heart failure.

@nl

P1433

Q34562883-5F647C99-66EC-41DB-A8DA-580A3C8C9A4A

P1476

Q34562883-2883FEF1-79EC-4AE6-952A-D3E1DD3D60D9

P2093

Q34562883-02B2AAF9-AA31-44B1-9136-CDF04C10D9EE

Q34562883-6F66FDF0-158A-4EDF-8928-F0EB229E5D09

Q34562883-A41B62B3-D072-4331-859C-2B48179811B5

Q34562883-A6A79846-70A7-4F71-9FC5-43A1EC9970DD

Q34562883-AD584B40-77A0-40E1-A1B7-94794793289F

Q34562883-BF7C2C8A-8A05-4881-80B5-916FC3956FEA

Q34562883-C427DF82-DB93-41BE-B2C8-07C38560F176

Q34562883-C503263D-FB3A-4329-AD3C-96FB778C9625

Q34562883-D1DC23BE-52DD-484B-B96F-A7A74F8DB201

P304

Q34562883-C256BCE9-5D0E-4EB7-B052-B9538EE6EC0E

P31

Q34562883-95F33338-09D0-41A4-8DA9-AF091C32D5F3

P356

Q34562883-8A9DFC3A-7E11-43AD-BF7E-6DE3B7AB8610

P407

Q34562883-DEFA26D8-270C-4C99-BE33-B49430BF8714

P433

Q34562883-9F4C2890-A733-4A2B-A323-940B7AE5EDF6

P478

Q34562883-A1D38ECF-A24D-4499-9D30-50514A2B0703

P577

Q34562883-4C901119-9FF9-4DEB-86AA-DE416716120E

P5875

Q34562883-265F85F2-E8D9-4927-92F0-EC783FE3F63B

P698

Q34562883-5A59576D-C5E2-4DC6-87B5-11E444498E53

P921

Q34562883-0BFC759B-0B05-471D-B31A-5567B2712BE5

Q34562883-1604D706-108F-42DF-A512-9C59D1885330

Q34562883-C7990B22-FADF-4D16-9DE3-887F82DA861C

P356

J.JACC.2006.03.060

P1433

Journal of the American College of Cardiology

P1476

A randomized clinical trial of ...... n patients with heart failure.

@en

P2093

Alberto Margonato

http://www.w3.org/2001/XMLSchema#string

Alessandra Rossodivita

http://www.w3.org/2001/XMLSchema#string

Altin Palloshi

http://www.w3.org/2001/XMLSchema#string

Carmen Silipigni

http://www.w3.org/2001/XMLSchema#string

Gabriele Fragasso

http://www.w3.org/2001/XMLSchema#string

Giliola Calori

http://www.w3.org/2001/XMLSchema#string

Mariagrazia Pala

http://www.w3.org/2001/XMLSchema#string

Ottavio Alfieri

http://www.w3.org/2001/XMLSchema#string

Patrizia Puccetti

http://www.w3.org/2001/XMLSchema#string

P304

992-998

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.JACC.2006.03.060

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

48

http://www.w3.org/2001/XMLSchema#string

P577

2006-08-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6841385

http://www.w3.org/2001/XMLSchema#string

P698

16949492

http://www.w3.org/2001/XMLSchema#string

P921